Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study

Nasal Obstruction Clinical Trial

Official title:

Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02952313
• Other study ID #: SPI-CP-301
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: August 2019

Study information

• Verified date: August 2020
• Source: Spirox, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to obtain outcomes data in subjects with severe to extreme class NOSE scores undergoing placement of the Spirox Latera Implant with or without concurrent septoplasty and/or turbinate reduction procedures in an operating room setting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. completion date: August 2019
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject has Nasal Obstruction Symptom Evaluation (NOSE) Score =55.

2. The subject has dynamic lateral nasal wall insufficiency as confirmed by Positive Modified Cottle Maneuver22.

3. The subject is =18 years of age.

4. The subject is willing and able to provide informed consent and comply with the study protocol.

5. The subject is seeking treatment for nasal airway obstruction due to Nasal Valve Collapse (NVC) and is willing to undergo nasal Implant procedure alone or with septoplasty and/or a turbinate reduction procedure in an operating room setting.

6. The subject has appropriate nasal and facial anatomy to receive Latera Implant.

7. The subject agrees to follow-up examinations through twelve (12) months post operatively.

8. The subject has failed a trial of appropriate maximal medical management [e.g., nasal steroids (at least 4 weeks); antihistamines; oral decongestants; nasal strips, stents, or cones]. Failure of maximal medical management may be from lack of effectiveness or inability of subject to tolerate.

Exclusion Criteria:

1. The subject is having a concurrent Functional Endoscopic Sinus Surgery (FESS) or sinuplasty.

2. The subject has had rhinoplasty within the past twelve (12) months.

3. The subject is planning to have other concurrent rhinoplasty procedure.

4. The subject is planning to have other rhinoplasty procedures or will use external dilators within twelve (12) months after the index procedure.

5. The subject has had septoplasty and/or inferior turbinate reduction within the past six (6) months.

6. The subject has, in the view of the clinician, inappropriate fixation on their nasal airway.

7. The subject plans to have any surgical or non-surgical treatment of their nasal valve, other than the index procedure, within twelve (12) months of the study.

8. The subject has a permanent Implant or dilator in the nasal area.

9. The subject has concomitant inflammatory or infectious skin conditions or unhealed wounds in the treatment area.

10. The subject currently has active nasal vestibulitis.

11. The subject has a history of nasal vasculitis.

12. The subject is a chronic systemic steroid or recreational intra-nasal drug user.

13. The subject has had a cancerous or pre-cancerous lesion and/or has had radiation exposure in the treatment area or chemotherapy.

14. The subject has polyps or pathology other than septal deviation and/or turbinate hypertrophy and/or lateral wall insufficiency that would contribute to airway obstruction.

15. The subject has a history of a significant bleeding disorder(s) that would prevent healing of the treatment area post procedure.

16. The subject has a known or suspected allergy to poly lactic acid (PLA) or other absorbable materials.

17. The subject has a significant systemic disease such as poorly controlled diabetes which, in the investigator's opinion, could pre-dispose the subject to poor wound healing.

18. The subject is currently using nasal oxygen or continuous positive airway pressure (CPAP).

19. The subject is not a candidate for procedures conducted under general anesthesia, managed anesthesia care (MAC) or conscious sedation.

20. If female, subject is known or suspected to be pregnant or is lactating.

Related Conditions & MeSH terms

• Nasal Obstruction

Intervention

Device:
• Nasal Implant

Locations

Country	Name	City	State
United States	ENT of Georgia	Atlanta	Georgia
United States	ENT & Allergy Center of Austin	Austin	Texas
United States	Beverly Hills Aesthetic Surgical Institute	Beverly Hills	California
United States	ENT Assoc. of South Florida	Boca Raton	Florida
United States	The Center for Sinus, Allergy & Sleep Wellness	Boynton Beach	Florida
United States	Chicago Nasal & Sinus Center	Chicago	Illinois
United States	Northwestern University	Chicago	Illinois
United States	Collin County ENT	Frisco	Texas
United States	ENT New Orelans	Marrero	Louisiana
United States	Madison ENT & Facial Plastic Surgery	New York	New York
United States	Ogden Clinic	Ogden	Utah
United States	Piedmont ENT	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Spirox, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stolovitzky P, Sidle DM, Ow RA, Nachlas NE, Most SP. A prospective study for treatment of nasal valve collapse due to lateral wall insufficiency: Outcomes using a bioabsorbable implant. Laryngoscope. 2018 Nov;128(11):2483-2489. doi: 10.1002/lary.27242. Ep — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Primary Efficacy Endpoint is the Percent of Treatment Responders	Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).	6 months post procedure
Primary	Primary Safety Endpoint: Nasal Procedure and Latera™ Device-related Adverse Events	Number of participants with a device-related or procedure-related adverse event	6 months post procedure
Secondary	Percent of Treatment Responders	Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).	1, 3 12, 18, and 24 months post procedure.
Secondary	Change in Nasal Airway Obstruction From Baseline Using the Visual Analog Scale (VAS).	Change from baseline in VAS score for ability to breathe through the nose. Participants provide scores on a scale of 0 (easy to breathe through the nose) to 100 (unable to breathe through the nose). Negative values for the change from baseline indicate improvement in symptoms.	1, 3, 6, 12, 18, and 24 months post procedure
Secondary	Subject Satisfaction Questionnaire	Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.	6 months
Secondary	Procedure and Device Related Adverse Events	Number of participants who experience procedure or device-related adverse events.	After 6 months and up to 24 months post procedure